SlimanoFRoessleCBlancC, et al.
Updates on prevention and treatment of melanoma: pharmacist involvements and challenges. Ann Pharm Fr2016;
74: 335–349.
2.
RobertCLongGVBradyB, et al.
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med2015;
372: 320–330.
3.
RobertCSchachterJLongGV, et al.
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med2015;
37: 2521–2532.
4.
AsciertoPALongGVRobertC, et al.
Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol2019;
5: 187–194.
5.
RobertCRibasASchachterJ, et al.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol2019;
20: 1239–1251.
ChatelutELe LouedecFMilanoG. Setting the dose of checkpoint inhibitors: the role of clinical pharmacology. Clin Pharmacokinet 2020; 59: 287–296.
9.
AgrawalSFengYRoyA, et al.
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer2016;
4: 72–82.
10.
BajajHWangXAgrawalS, et al.
Model-based population pharmacokinetic analysis of nivolumab in patient with solid tumors. CPT Pharmacometrics Syst Pharmacol2017;
6: 58–66.
11.
AhamadiMFreshwaterTProhnM, et al.
Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol2017;
6: 49–57.
12.
FreshwaterTKondicAAhamadiM, et al.
Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer2017;
5: 43–50.
ZhaoXSuryawanshiSHruskaM, et al.
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol2017;
28: 2002–2008.
16.
LevenCPadelliMCarréJ-L, et al.
Immune checkpoint inhibitors in melanoma: a review of pharmacokinetic and exposure-response relationships. Clin Pharmacokinet2019;
58: 1393–1405.
17.
BayleABesseBAnnereauM, et al.
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed dose regimen: what is the economic impact?Eur J Cancer2019;
113: 28–31.
18.
LongGVTykodiSSSchneiderJG, et al.
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol2018;
29: 2208–2213.
LalaMLiMSinhaV, et al.
A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.J Clin Oncol2018;
36: 3062.
GoldsteinDAGordonNDavidescuM, et al.
A pharmacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer. J Natl Cancer Inst2017; 109–119.
23.
de LemosMLKungCWaigneinS.Efficacy of nivolumab four-weekly dosing schedule based on body weight. J Oncol Pharm Pract2019;
25: 961–963.
24.
MurphyWJLongoDL.The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA2019;
321: 1247–1248.
25.
McQuadeJLDanierCRHessKR, et al.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol2018;
19: 310–322.
